Familial Hypercholesterolemia Identification Algorithm in Patients with Acute Cardiovascular Events in A Large Hospital Electronic Database in Bulgaria: A Call for Implementation

Ivo Petrov · Arman Postadzhiyan · Dobrin Vasilev · Ruslan Kasabov · Mariya Tokmakova · Fedya Nikolov · Veselin Istatkov · Boyang Zhao · Dimiter Mutafchiev · Reneta Petkova

Received: November 17, 2020 / Accepted: December 11, 2020 / Published online: March 23, 2021
© The Author(s) 2021

ABSTRACT

Background: Familial hypercholesterolemia (FH) is a genetic disorder characterized by a high level of low-density lipoprotein cholesterol (LDL-C) and is an important cause for premature cardiovascular disease. Because of underdiagnoses, an acute event is often the first clinical manifestation of FH. There are limited data on the prevalence and treatment of FH among adults admitted for treatment of acute cardiovascular events in Bulgaria. Our objective was to assess the proportion and management of FH patients from those admitted to hospital for treatment of acute symptomatic acute atherosclerotic cardiovascular events (ASCVD), the achievement of LDL-C targets of European Society of Cardiology/European Atherosclerosis Society guidelines and related public healthcare resources.

Objective: Digitalized healthcare records for patients admitted for treatment of symptomatic ASCVD acute events between August 2018 and August 2019 were used for the analysis. Five cardiology hospitals provided data for hospitalizations, laboratory tests, and ambulatory follow-ups up to February 2020. Patients' cardiovascular events in Bulgaria. Our objective was to assess the proportion and management of FH patients from those admitted to hospital for treatment of acute symptomatic acute atherosclerotic cardiovascular events (ASCVD), the achievement of LDL-C targets of European Society of Cardiology/European Atherosclerosis Society guidelines and related public healthcare resources.

Objective: Digitalized healthcare records for patients admitted for treatment of symptomatic ASCVD acute events between August 2018 and August 2019 were used for the analysis. Five cardiology hospitals provided data for hospitalizations, laboratory tests, and ambulatory follow-ups up to February 2020. Patients’

M. Tokmakova · F. Nikolov
Department of Cardiology, Medical University of Plovdiv, Plovdiv, Bulgaria

V. Istatkov · B. Zhao · D. Mutafchiev
 Sqilline, Danny Platform—Analytics Platform for Real-World Data, Sofia, Bulgaria

R. Petkova (✉)
Department of General Medicine, Amgen Bulgaria, Sofia, Bulgaria
e-mail: rpetkova@amgen.com
hospital and ambulatory records were linked, and medical histories were extracted via a specifically developed algorithm, and analyzed. Outcomes included the proportion of patients classified as FH as defined by the Dutch Lipid Network Criteria (DLNC), use of lipid-lowering therapy, LDL-C achieved by 1, 3, 6, and 12 months post-index event, and public resources spent on hospital and ambulatory treatment.

**Results:** We reviewed 11,090 hospital records of patients admitted for treatment of acute events in the period August 2018–August 2019 with ICD codes for ASCVD (Supplementary Table S3). FH was identified in 731 (6.6%) patients, with DLNC score ≥ 3, (682 with coronary artery disease, 32 with cerebrovascular disease, and 17 with peripheral artery disease). We did not find the criteria for FH in 5797 patients. The remaining 4562 records were inconclusive due to lack of data in the hospital dossier. Less than half of FH patients (274/731, 37%) were discharged on high-intensity statin therapy prescribed (34/731, 5%) with combination therapy. The vast majority (96.2% with LDL-C ≥ 1.8 mmol/l) had poorly controlled LDL-C during the first year after discharge. Patients with a probable/definite DLNC score ≥ 6 points and those with recurrent events contributed to the higher cost paid both by the healthcare system and the patients themselves.

**Conclusion:** These findings reinforce the need for more aggressive lipid-lowering therapy, and underline the efficiency of using an electronic medical records search tool to support physicians in improving early FH diagnosis, aiming to minimize residual and future ASCVD events among FH patients and their family members. Supplementary file1 (MP4 21838 KB)

**Keywords:** Dyslipidemia; Familial hypercholesterolemia; Dutch lipid network criteria (DNLC); Electronic hospital database (EMR); Health care resource utilization (HRU); Coronary artery disease (CAD); Peripheral artery disease (PAD); CVD (coronary, peripheral, and cerebral (arterial) disease)

**Key Summary Points**

**Why carry out this study?**

There are limited data on the proportion and management of familial hypercholesterolemia (FH) among adults admitted for treatment of acute cardiovascular events. Because of underdiagnosis, an acute event is often the first clinical manifestation of FH.

**What was learned from the study?**

This retrospective observational study aimed to use specifically designed software to enable data extraction of routinely treated patients admitted for ASCVD acute events to screen for FH by using all available medical records.

The vast majority (96.2% with LDL-C ≥ 1.8 mmol/l) had poorly controlled LDL-C during the first year after discharge. Patients with probable/definite DLNC score > 6 points and those with recurrent events contributed to the higher cost paid both by the healthcare system and the patients themselves.

The implementation of the automated screening tool may be of advantage for physicians, reinforcing early FH identification and improving patient pathways and outcomes.

**DIGITAL FEATURES**

This article is published with digital features, including a summary slide and video abstract, to facilitate understanding of the article. To
INTRODUCTION

Familial hypercholesterolemia (FH) is a common genetic disorder, which causes accelerated atherosclerosis, premature cardiovascular (CV) disease and increased CV morbidity and mortality [1]. While the prevalence of FH ranges from approximately 1 in 250 to 1 in 500, there are limited data regarding the number of patients with FH who are hospitalized for an acute CV event [2, 3]. Moreover, systematic screening and early identification of FH during hospitalization would improve patient treatments and outcomes. For example, compared to patients without FH, those with FH and acute coronary syndrome (ACS) are more than twice as likely to experience subsequent CV events during the first year following discharge, despite concomitant use of high-intensity statin therapy [4–8]. During hospitalization, screening for FH can be performed at low cost using specifically designed algorithms, which search electronic medical records (EMR) for hospital admissions, patient histories, and laboratory tests. Moreover, early identification and treatment of patients with FH and their family members may reduce the risk of recurrent CV events. In Bulgaria, FH has only recently (2017) been added to the list of ICD codes for disease reimbursement by the National Health Insurance Fund (NHIF).

We used specifically designed software to search the EMR of patients admitted to hospital for the treatment of an acute CV event and to identify those with undiagnosed FH.

METHODS

Study Objective and Outcomes

The primary outcome was the proportion (%) of patients with undiagnosed FH.

Secondary outcomes included: (1) patient demographics, clinical characteristics, and lipid-lowering therapy (LLT); (2) achievement of the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) LDL-C goal of ≤1.8 mmol/L 1, 3, 6 and 12 months after the index hospitalization; (3) recurrent events at index hospitalization and time to subsequent event(s); (4) healthcare resource utilization (HRU) related to CV events, specified as ambulatory medication treatment cost after index hospitalization, paid with public money, and the cost paid out-of-pocket.

Data Source and Inclusion Criteria

This retrospective database analysis used digitalized records across five hospitals and the EMR software to extract data for patients admitted for an acute CV event in the period August 2018–August 2019 (index hospitalization).

The search algorithm is described in Fig. 1; the ICD-10 codes are listed in Table S3.

Three patient cohorts were identified: (1) FH with Dutch lipid network criteria (DNLC) score ≥3 points, (2) Non-FH, and (3) Unknown (insufficient data to calculate DLNC score).

The Unknown group had to be defined in our database because of missing lipid profiles needed to calculate Dutch score in some patients. In these cases, it was not possible to further derive this information because there is no regulation in Bulgaria for patients with ASCVD for lipid profile testing.

Data Collection

Data were extracted from hospital dossiers, including hospitalization records, laboratory tests, and ambulatory visits (up to February 2020). Patient demographics, ASCVD history, comorbidities, LLT medication, type of index CV event, and risk scores (calculated during hospitalization) were extracted.

The follow-up period was defined as 6–12 months from the index hospitalization until 1 February 2020 (end of follow-up period). The following groups were analyzed:

1. Patients (n = 158) who visited the same hospital ambulatory department at 1, 3, 6 or 12 months, and had at least 1 LDL-C

view digital features for this article go to https://doi.org/10.6084/m9.figshare.13360208.
measurement. The group were analyzed for LDL-C achievement according to ESC/EAS 2016 goals

(2) Patients (n = 174) who had a change in LLT dose or type of medications during the visits. This group was analyzed for more precise monthly costs of ambulatory treatment.

LLT before admission and at the time of hospital discharge were extracted. For patients who visited the same hospital during the follow-up period, ambulatory LLT post-index hospitalization was also extracted.

HRU included prescribed ambulatory LLT following discharge and recurrent hospitalizations. Published list prices were used for ambulatory LLT (dependent on the level of reimbursement and price on the date of discharge). For each patient, total ambulatory LLT cost for 1 month was calculated in local currency (BGN) as amounts paid with public money (NHIF-paid) and co-paid by the patient (patient-paid).

Data Extraction

We used the Danny Platform [9], which tracks patients between different hospitals, laboratories, and others. This platform does not store personal information and the patient’s personal identification number is anonymized using a hashing algorithm; the resulting hashed personal number is the same across all sources and allows patients to be tracked without identifiable details.

While some incoming data were already parameterized, a substantial amount was free text, typed manually by doctors and/or other healthcare professionals. Additional pre-processing and extraction steps were performed

Fig. 1 Flowchart of the search algorithm
upon data import. This included the aggregation of transactional-level data into a unified data structure amenable for interpretation and NLP (Natural Language Processing) entity extraction. Specific parameter values were extracted and normalized using several approaches, i.e., regular expressions, string matching, word similarities, and more advanced NLP approaches. The suitable approach chosen was contingent on a continuous detailed analysis of the free text and the parameters.

Data Normalization

Upon parameter value extraction, the values required additional normalization due to the high heterogeneity in syntax across the different data sources. A rule-based approach was used to normalize each parameter. When the system was unable to find a normalization rule, the parameter was flagged and required additional follow-up by the quality control experts to create new normalization rules. The database kept an up-to-date list of rules for the continuous parsing and persistence of incoming data.

Identification of Patients With FH

We assessed the presence of FH using the validated DLNC algorithm [10], which is approved for clinical use in Bulgaria by the NHIF. For patients on LLT at index hospitalization, we estimated untreated LDL-C by multiplying the on-treatment LDL-C by a correction factor [23] based on LLT type and dose, which is accepted by the NHIF in general practice.

Patients with DLNC scores 3–5 were defined as possible FH diagnosis, those with DLNC scores 6–8 as probable FH, and those with DLNC ≥ 9 as definite FH. Due to the small sample size, definite and probable FH were combined into one group, “definite/probable”, and patients in this group considered to have clinically defined FH.

An NLP algorithm was developed to identify patients with arcus cornealis, tendon xanthoma, or stated FH. The records of these patients were verified by physicians, and a DLNC score awarded wherever appropriate.

Statistical Analysis

Patient demographics and clinical characteristics were summarized using descriptive statistics. Categorical variables were reported as numbers and percentages (n, %). Continuous variables were reported as mean ± standard deviation (SD) for normally distributed data, and median and 25%–75% percentiles (Q1–Q3) used for non-normally distributed data.

DLNC scores were calculated for patients having a complete medical dossier, and three patient cohorts were identified: (1) FH with DLNC score ≥ 3 points, (2) Non-FH, and (2) Unknown (insufficient data to calculate DLNC score).

Statistical significance for a given variable between the FH groups was assessed with the Chi-squared test (for categorical variables) or the (non-parametric) Mann–Whitney U test (for numerical variables). P values < 0.05 were considered statistically significant. Shapiro–Wilks tests and Levene’s tests were performed to test for normality and homogeneity of variance, respectively. Time-to-event analysis was performed using the Kaplan–Meier method, with 95% confidence intervals estimated using Greenwood’s formula.

RESULTS

Patient Disposition

Among 11,090 patients with index hospitalizations for acute CV events during the period 1 August 2018–1 August 2019, our DLNC algorithm identified 731 (6.6%) with FH: possible, n = 325 (44%), and probable/definite, n = 406 (56%) (Fig. 1). A total of 5797 patients were classified as Non-FH, while 4562 had incomplete data and were excluded from the analysis.

Patient Characteristics

Table 1 summary demographics and baseline characteristics for patients with and without FH. Data for Possible vs Probable/Definite FH is reported in Supplementary Table S1.
Compared to patients without FH, those with FH were younger (52.5 vs. 65.4 years); the majority (81%) of FH patients were aged 41–60 years at the index hospitalization for an acute CV event, whereas most (68%) patients without FH were aged > 60 years.

One-third (33%) of FH patients were female, compared to 40% of Non-FH patients. Approximately one-third (36%) of FH patients had a history of prior CV events, compared with only 5% of Non-FH patients. In both groups, coronary artery disease (CAD) was the most common cause of index hospitalization (FH, 93%; Non-FH, 82%); a cause of CVD was more likely among non-FH patients (16% vs. 4%, respectively); across both groups, few patients were hospitalized for peripheral artery disease (PAD). The presence of comorbidities was similar among patients with and without FH.

Mean age was similar in the possible and probable/definite FH groups (52.3 and 52.6 years, respectively), and the majority of patients were aged 41–60 years at index hospitalization (probable/definite, 80%, possible FH, 82%) (Supplementary Table S1). Patients with probable/definite FH were more likely to have a prior CV event (43% vs. 26%). Fewer possible FH patients were smokers (3.7% vs. 23.2%, \( p < 0.001 \)) and diabetic (10% vs. 15%, \( p < 0.001 \)).

**LDL-C Levels and Laboratory Measurements**

LDL-C was either calculated (Friedewald’s formula) or directly measured (as per routine laboratory practice in cases of triglyceride level > 4.5 mmol/l). Compared with the Non-FH group, median (Q1, Q3) LDL-C was higher among patients with FH: 4.2 (3.3–4.8) vs. 2.9 (2.1–3.7) mmol/l.

Median (Q1, Q3) LDL-C was similarly high in the possible and probable/definite FH groups: 4.1 (2.9–4.6) and 4.3 (3.5–5.2) mmol/l, respectively. Total cholesterol was also high: 5.9 (4.8–6.5) and 6.1 (5.3–7.3) mmol/l, respectively.

Cardiac markers to assist diagnosis measured in routine clinical practice median (Q1, Q3), creatine phosphokinase and C-reactive protein (cardiac markers used to diagnosis FH), were higher in the FH group (96 (23–202.5) and 8.3 (3–20.6), respectively, compared to the Non-FH group [75 (22–134) and 8.1 (2.3–31.3), respectively]. Creatinine and troponin plasma levels were similar in FH and non-FH patients.

**LLT**

LLT use before index hospitalization and at discharge is summarized in Supplementary Fig. S1.

Data for LLT use before index hospitalization were not available for two-thirds [495 (68%)] of FH and three-quarters [4429 (76%)] of Non-FH patients, suggesting they may have been untreated or LLT was not recorded. Among patients with data available, most patients in the FH and Non-FH groups were treated with statin monotherapy [218/236 (92%) and 1309/1368 (95%)]. Only 29% (67/232) and 18% (245/11,357) of FH and non-FH patients were treated with high-intensity statins. LLT use in patients with possible or probable/definite was similar.

Data for LLT after discharge were available for three-quarters [544/731 (74%)] of FH and 41% (2389/5797) of Non-FH patients. The reasons for the missing records may be differences in hospital IT systems and/or the possibility for providing the data for analysis. Another reason may be that home therapy is not included in the information reported daily to the NHIF as it is within GPs’ responsibility.

Compared with LLT before index hospitalization, use of high intensity statins among patients with FH increased at discharge [274/541 (50%) and 67/232 (29%), respectively]. High-intensity statin uses also increased among Non-FH patients. Only 6.2% (34/544) of FH and 2% (50/2389) of Non-FH patients received combination therapy at discharge. Notably, CV events led to an increase in the intensity of statin treatment for FH (from 29 to 51%) versus (18–40%) for the Non-FH group (\( p < 0.001 \)).
Table 1 Baseline demographic and clinical characteristics of patients with FH (731) and Non-FH (5797) by diagnostic algorithm

| Characteristic                          | DLNC |          |          |          |          |          |          |
|----------------------------------------|------|----------|----------|----------|----------|----------|----------|
|                                        | FH \(n = 731\) | Non FH \(n = 5797\) | \(p\) value |
| Age at index hospitalization years, mean ± SD | 52.5 ± 8.1 | 65.4 ± 11.6 | < 0.001   |
| Age groups at index hospitalization, \(n\) % (95% CI) |          |          |          |          |          |          |          |
| \(\leq 40\)                            | 45   | 136      | 2.3 (2.0–2.8) | < 0.001   |
| 41–50                                  | 231  | 522      | 9.0 (8.3–9.8) | < 0.001   |
| 51–60                                  | 359  | 1218     | 21.0 (20.0–22.1) | < 0.001   |
| \(> 60\)                               | 96   | 3921     | 67.6 (66.4–68.8) | < 0.001   |
| Female, % (95% CI)                     | 243  | 2326     | 40.1 (38.9–41.4) | < 0.001   |
| Height, cm, mean ± SD                  | 173.8 ± 11.4 | 169.9 ± 9.3 | 0.003     |
| Weight, kg mean ± SD                   | 89.5 ± 19.7 | 83.6 ± 20.5 | 0.004     |
| BMI, kg/m² mean ± SD                   | 29.7 ± 5.7  | 28.9 ± 6.0  | 0.154     |
| Comorbidities, \(n\) %                 |          |          |          |          |          |          |          |
| Hypertension                           | 50.8 (47.1–54.4) | 53.3 (52–54.6) | 0.213     |
| Diabetes                               | 12.7 (10.5–15.3) | 16.8 (15.9–17.8) | 0.006     |
| Prior CV events                        | 35.7 (32.3–39.2) | 5.3 (4.7–5.9) | < 0.001   |
| CV index event, \(n\) %                |          |          |          |          |          |          |          |
| CAD                                    | 93.3 (91.2–94.9) | 81.6 (80.6–82.6) | < 0.001   |
| CVD                                    | 4.4 (3.1–6.1)   | 15.6 (14.7–16.6) | < 0.001   |
| PAD                                    | 2.3 (1.5–3.7)   | 2.7 (2.4–3.2)   | 0.593     |
| Objective measures median (Q1–Q3)      |          |          |          |          |          |          |          |
| TH, mmol/l                             | 6 (5.1–6.9)    | 4.7 (3.8–5.7)   | < 0.001   |
| LDL-C, mmol/l                          | 4.2 (3.3–4.8)  | 2.9 (2.1–3.7)   | < 0.001   |
| TGL, mmol/l                            | 1.8 (1.2–2.7)  | 1.4 (1.0–2.0)   | < 0.001   |
| HDL-C, mmol/l                          | 1.1 (0.9–1.4)  | 1.1 (0.9–1.4)   | 0.274     |
| Creatinine, mmol/l                     | 87.4 (75–100)  | 90 (77–110)     | < 0.001   |
| CFK, IU/l                              | 96 (23–202.5)  | 75 (22–134)     | < 0.001   |
| CRP, mg/l                              | 8.3 (3.0–20.6) | 8.1 (2.3–31.3)  | 0.877     |
| Troponin, ng/L                         | 0.2 (0.0–1.2)  | 0.2 (0.0–0.6)   | 0.146     |
| SYNTAX, score median (Q1–Q3)           | 10.5 (6–16)    | 12.0 (8–18)     | 0.177     |
| GRACE, score median (Q1–Q3)            | 145 (139–152)  | 155 (143–173)   | < 0.001   |
CV Risk Scores

CV scores were calculated using SYNTAX (coronary anatomical) and GRACE (clinical) scores.

SYNTAX is an angiographic grading tool to determine the complexity of CAD, a useful differentiator for the outcome of patients undergoing three-vessel PCI. The high scores indicate complex coronary anatomy and represent greatest risks to patients undergoing PCI, bigger therapeutic challenge and worsen prognosis. SYNTAX score was found to be an independent predictor of long-term major adverse cardiac and cerebrovascular events (MACCE) and of death in patients treated with PCI [23, 24].

A residual SYNTAX score > 8 after PCI was associated with significant increases in the 5-year risk of death and of the composite of death, myocardial infarction (MI), and stroke, and any residual SYNTAX score > 0 was associated with the risk of repeat intervention [25]. No difference in median (Q1–Q3) SYNTAX score was observed between FH and Non FH group 10.5 (6–16) and 12.0 (8–18); \( p = 0.176 \). A modest increase between the probable/definite and possible FH groups, median 12.5 (8.5–16.2) vs. FH 7 (5.2–16.0) \( p = 0.169 \).

GRACE is a system to stratify patients with diagnosed ACS to estimate in-hospital and 6-month to 3-year mortality. Median (Q1–Q3) GRACE score was similar in the FH and Non FH group 10.5 (6–16) and 12.0 (8–18); \( p = 0.176 \).
Among all FH patients, 158 had available information for out-patient visits in the same hospitals—constituting to the cohort we followed up for 6 months and 39 patients for 12 months. LDL-C ambulatory results are shown at Fig. 2. Among patients with 12-month follow-up only 5% (4/79) reached the 2016 recommended ESC/EAS goal while on LLT therapy and had their LDL-cholesterol levels of 1.8 mmol/l or lower between the 1st and 3rd month; 7.4% (2/29) between the 3rd and 6th month.

**Recurrent Events in FH Patients**

A total of 261 FH (35.7%) patients had a documented history of prior CV events [CAD, \(n = 229\) (88%); PAD, \(n = 15\) (5.7%); CVD, \(n = 17\) (6.5%)] with the index hospitalization being the most recent event (Fig. 3). For this group, their previous CV events mentioned in the medical history were manually annotated. Among FH patients with a documented history of prior CV events, 154 (59%) had at least 1 prior event, 64 (24%) had 2 prior events, 28 (11%) had 3 prior events, and 15 (6%) had more than 3 prior events. In time-to-event analysis, we observed a progressive decrease in time to the next CV event with increasing numbers of prior CV events (median time dropped from 29 to 22 months) (Supplementary Fig. S3). Following the index hospitalization, 135 (18%), FH patients had recurrent CV events which required hospitalization during the follow-up period (Table 2). A substantial proportion of CAD patients had subsequent re-hospitalizations: \(n = 118\), 87.4% (95% CI, 80.8–92.0); with PAD: \(n = 10\), 7.4% (4.1–13.1); and with CVD: \(n = 7\), 5.2% (2.5–10.3).
HRU

Total ambulatory costs are reported in Table 3. Costs were higher in the probable/definite FH group than in the possible FH group.

Total 1-year treatment costs could not be calculated for the FH group due to lack of data for implants and additional charges paid during hospitalization. FH patients with recurrent events (Table 4) had higher costs due to repetitive hospitalization.

Patients who visited hospitals after the index event for medication adjustments had lower ambulatory costs of 89.60 (111.90) BGN than others (lost to follow-up), 95.70 (110.70) BGN.

DISCUSSION

To the best of our knowledge, this is the first study to assess FH inpatients hospitalized for acute CV events and their clinical management (in-hospital and ambulatory) in Bulgaria. This study used anonymized electronic data from 11090 hospital dossiers with ICD (Supplementary Table S3) codes for ASCVD, across large academic hospitals in three different regions of Bulgaria (southwest, northwest, and south central). We identified 6.6% (1:15) of patients treated for ASCVD to have FH; these tended to be younger individuals, with poorly controlled LDL-C during the follow-up period. We identified 44% of patients to have possible FH and 56% to have probable/definite FH. Due to the lack of national data, we cannot compare our results with the general population of ASCVD patients in Bulgaria. Importantly, many patients were not recognized as FH during their index hospitalization. In our sample, we worked only with records which had available data to calculate DLNC scores, predominantly by LDL-C levels, LLT with dose to calculate back untreated LDL-C values by regression coefficients [22], and family histories for prior hospitalizations events. We did not find mention of relatives with FH or premature atherosclerosis and arcus cornealis, but for xanthomas we found 4 patients. Given the incompleteness and high numbers of medical records (4562) marked as Unknown and excluded from the analysis, we may estimate that the true FH proportion is under-represented, and that FH diagnosis is widely unrecognized. Thus, many individuals are left without appropriate therapies to control their elevated CV risk.

The only study describing clinical management of HR and VHR subjects with FH in Bulgaria [11] highlights that many subjects (73.6%) with FH have first-degree relatives with known risk factors such as coronary and/or vascular disease or high LDL-C levels; however, this important information was missing in the hospital dossiers, suggesting that the proportion of FH patients with ≥ 6 points could be even higher.

A systematic review and meta-analysis of 19 studies [12] conducted in various countries reported FH prevalence in the general population as 0.4% (1:250). One potential reason for higher figures in the present study could be the difference in the population. Participants in our study were in- and out-patients admitted for treatment of acute ASCVD events, who were likely to have cardiovascular risk factors and clinical disease severe enough to warrant intervention. Hence, our result may be more useful for healthcare professionals than population-based studies, because they treat similar patients in routine clinical practice. Another potential reason for the higher prevalence could be the use of different diagnostic criteria, e.g., DLNC, which is clinically established and acknowledged by the National health reimbursement fund. In the present study, 93% (n = 682) of the FH cohort were hospitalized for CAD. Given the high proportion of coronary patients, even though this figure is a proportion value, not the prevalence, it could be deemed to be a reference value for the prevalence of ACS in patients with FH in Bulgaria.

Several studies have reported the prevalence of FH in patients with ACS. For example, in a Swiss multicenter study, SPUM-ACS, (Special Program University Medicine-Acute Coronary Syndrome) [5, 6] of 4778 patients with ACS, 1.6% (n = 78) had probable/definite FH (DLNC > 5 points). However, when limited to patients with premature ACS (defined as men aged ≤ 55 years and women ≤ 60 years), the FH prevalence increased to 4.8%. In an analysis, the
EUROASPIRE IV survey [4] (European Action on Secondary and Primary Prevention through Intervention to Reduce Events) which included c.7000 patients hospitalized for ACS or revascularization procedures (79 large academic hospital centers), the prevalence of FH was estimated at 8.3% and increased to 15.4% when restricted to 2212 patients ≤ 60 years. Singh A et al. [13] reported that, based on the YOUNG-MI registry (1996 adults), nearly 1 in 10 patients with MI (9%) met criteria for clinically defined FH, at or below the age of 50 years.

Other smaller studies have also estimated the prevalence of FH in different countries: Pang et al. [8] found FH prevalence to be 14.3% among 175 patients age < 60 admitted in cardiology settings in Australia, while Al-Rasadi et al [14] reported FH prevalence of 3.7% in a cohort of 3224 patients with ACS in the Arabian Gulf. The wide variations in the reported estimates in these studies may be related to the variability of the true prevalence of FH across distinct potentially genetically diverse populations [15] and to the criteria used to define FH [16]. Although the prevalence varied widely, it is much higher than in the general population, underlying the importance of lipid level control in the prevention of cardiovascular diseases.

Identification of FH is important, as the disorder is associated with early onset of CHD. In our study, we found that one-third of FH patients (n = 261, 35%) had prior CV events.

### Table 2 Number of patients and number of subsequent hospitalizations

| CV event (index hosp.) | n  | % (95% CI) | 1 incident | 2 incidents | 3 incidents | 4 incidents |
|------------------------|----|-----------|------------|-------------|-------------|-------------|
| CAD                    | 118| 87.4% (80.8–92.0) | 103 | 11 | 2 | 2 |
| PAD                    | 10 | 7.4% (4.1–13.1)    | 6  | 4  | 0 | 0 |
| CVD                    | 7  | 5.2% (2.5–10.3)    | 5  | 2  | 0 | 0 |
| Total                  | 135| 100.0%      | 114 | 17 | 2 | 2 |

Subsequent hospitalization is a hospitalization after the index one until the end of the observation period (February 2020)

$n$ number of patients

### Table 3 Total ambulatory 1 month costs for FH patients after index hospitalization

| Cost of FH patient ambulatory treatment, BGN mean ± SD ($n = 640/731$) |
|---------------------------------------------------------------|
| NHIF reimbursed amount                                         |
| 43.70 ± 85.30                                                  |
| Patient paid amount                                           |
| 52.00 ± 40.70                                                  |
| Total amount 1 month                                          |
| 95.70 ± 110.70                                                 |

The cost for ambulatory treatment is extracted from the discharge documents

$n$ number of patients, $SD$ standard deviation.

### Table 4 Cost for FH patients with a recurrent event after index hospitalization in the 6 months follow-up period

| Cost of hospitalization of FH patients with a current event in 6 months after index hospitalization, BGN mean ± SD ($n = 120$) |
|-------------------------------------------------------------------------------------------------------------------------------|
| Hospitalization cost                                                                 |
| 6942.90 ± 2894.80                                                                 |

A total of 120 patients had 249 events leading to hospitalization in the 6 months period, index hospitalization included. From all patients in the FH group, only patients that have reoccurring events that lead to hospitalization in the 6 months after the index hospitalization follow-up period are included when calculating numerical variables. Index hospitalization is included. Hospitalization prices change in time, thus are taken from a price list based on date of each hospitalization

$n$ number of patients

Adv Ther (2021) 38:2323–2338
which is sevenfold higher compared with Non-FH \((n = 305, 5.2\%)\).

In the present study, the proportion of possible (3–5) and probable/definite (≥ 6) FH patients who used LLT were similar.

Statins are the recommended first-line therapy to lower LDL-C after acute events. Large-scale evidence from randomized control trials and meta-analyses has shown that long-term statin therapy reduces cardiovascular events by 25% per year for every incremental LDL-C reduction of 1 mmol/l. [26] In the history part of hospital dossiers, we found records for LLT in 236 (32%) of FH, with only one-third on high-intensity therapy and few being treated with combination therapy. In addition, we found that for only a half of the FH patients, were the statin dose and combinations recorded properly in the discharge dossier. One possible reason may be the same as one of the limitations of this study, that is, working only with documentation and a retrospective design. However, our findings are consistent with numerous previous reports that FH patients tend to receive LLT relatively late, when severe atherosclerosis has developed, so the efficacy may be reduced. More effective lipid-lowering strategies include high-dose statins in combination with PCSK9 or ezetimibe [17, 18]. While treatment of CHD remains to be optimized, statins can substantially improve the prognosis, as modest doses can reduce the risk for CAD by about 80% in patients with FH [19].

The results of this study regarding LDL-C target achievement at 1,3,6 and 12 months post-index hospitalization are similar to those previously published with only 3.8% of the patients reaching the 2016 risk-based goal in the 3rd and 6th months. Multiple issues may potentially contribute to the lack of LDL-C reduction. Under-dosing and statin discontinuation/poor adherence to therapy are acknowledged as key contributors, and have been linked to poorer clinical outcomes [1, 10, 20]. The healthcare system in Bulgaria is based on the reference principle and therefore restrictive, waiting for larger markets to introduce new products and deliver data showing results from the change in therapy. Partial reimbursement and required co-payment out of the pocket may be another reason for an unsatisfactory level of mono- and combination therapy prescribed, and for an inadequate LDL-C reduction. After the index event, overall patients, were under-treated because LDL-C ≤ 1, 8 mmol/l were attained in roughly in 1 in 26 FH patients (Fig. 2).

Our analysis of ambulatory records shows that 158 FH patients visited the same hospital (178 visits) during the follow-up period. According to national guidelines, the patient is under the cardiologists’ care over 12 months post-event period. Upon discharge, a patient is free to decide if he/she stays for 1 year with the hospital ambulatory department or goes back to its resident cardiologist by territory, another town, or municipality. Upon discharge, all patients are given a cost-free examination within 30 days post-hospitalization in the hospital, as per NHIF guidelines. Our finding shows that, by the first month, only 33 patients benefited from the recommended free-of-charge examination, 79 came back after the first to third month, 27 after the third by sixth month, and 39 after the sixth to twelth month post-index hospitalization. LDL-C achievement according to 2016 ESC/EAS guidelines for LDL-C ≤ 1, 8 mmol/l reached only 5% at the third and 7% at the sixth month. The results are presented in Fig. 2. Our findings are supported by the previously reported 5% of VHR patients reaching LDL-C ≤ 1, 8 mmol/l in Bulgaria. [11] The recently updated 2019 joint ESC/EAS guidelines recommend even more stringent goals and aggressive therapy for FH patients, aiming to optimize LDL-C reduction by uptake of high-intensity statins to achieve both a 50% reduction and an even lower LDL-C goal of < 1.4 mmol/l for patients with high or very high risk. Reducing LDL-C from above 2 mmol/L to below 1.4 mmol/L could offer an 11% relative reduction in CV events and a 5% relative reduction in mortality [21], and thus offer considerable benefits for FH patients who are classified as very high risk.

This is the first study that calculates the direct cost for treatment of FH patients after hospitalization. The cost for implants is not included because of lack of information in the medical records. The total cost paid for
ambulatory treatment is based on the medications listed in the discharged documents for ambulatory treatment. The NHIF amount is extracted from the NHIF public list for ambulatory treatment accounting for the date of discharge, the level of reimbursement, and patient co-payment. The average monthly cost for treatment is higher for probable/definite FH patients (103.50 ± 124.30) compared with the total FH group (95.70 ± 110.70) and with the Possible FH (83.00 ± 82.70) (Fig. 4).

Patients who visited their cardiologists post-index event and had adjustment of the therapy (dose/type) paid a lower cost (Table 5) for ambulatory treatment (89.60 ± 110.90) compared with the total FH group (95.70 ± 110.70) and the Probable/Definite (103.50 ± 124.30) subgroups, underlying the need for regular check-ups with the treating physicians. More costly are patients with recurrent events leading to hospitalization after the index visit (Table 4).

Our study has several limitations and the results should be interpreted with caution. One is the retrospective design and the nature of an e-database analysis working only with what is available in the hospital records. We used the written information listed in electronic hospital records to calculate DLNC scores with detection rates coming primarily from LDL-C values and histories of prior CV events and index events, missing other important clinical criteria of the diagnostic algorithm such as tendon xanthomas, corneal arcus, information for first degree relatives with previous events, and elevated LDL-C, genetic analysis. Thus, our estimate should not be compared with prevalence studies because the true proportion of FH patients is under-estimated, and we had a high number (4562/11,090) of dossiers with insufficient information. Secondly, cholesterol levels have been shown to decrease 24 h after hospital admission, and so, e.g., we could not be certain if lipid results described in the hospital records are measured from the first blood drawn in the emergency department. In addition, the patients included were not evaluated for possible secondary causes for dyslipidemia, such as hypothyroidism or nephrotic syndrome, due to limited information in the electronic records. An additional limitation was our inability to adjust the healthcare resources spent for FH treatment for adherence to treatment. Given the fact that EMR is relatively new to healthcare providers, it is possible that providers may prefer to record much patient information via free text. NLP is a lengthy and expensive task, limiting the ability to use the unstructured information, and more generally speaks to the challenge of identifying FH patients in e-databases retrospectively.

Lastly, these results are not necessarily applicable for other e-database analyses that may capture different types of healthcare practitioners.

A strength of our study is that we have pointed out the need for supporting tools to unburden clinicians in the emergency department of interventional cardiology clinics. Such a tool may remind a patient with an acute cardiovascular event that it carries a higher probability of FH diagnosis. Adding to our tool a drop-down suggestion list with still missing information to calculate DLNC scores will prompt more thorough clinical examination and supplement the diagnosis. We have attempted for the first time to show the higher costs generated for FH patients due to under-diagnoses and under-treatment.

**CONCLUSIONS**

Early diagnosis and treatment are crucial for improving outcomes in FH patients. In hospital, 

| Cost for FH patients with ambulatory follow-up visits BGN mean ± SD | (n = 174) |
|---------------------------------------------------------------|---------|
| NHIF-reimbursed amount                                       | 43.10 ± 36.10 |
| Patient-paid amount                                          | 46.50 ± 32.20 |
| Total amount 1 month                                         | 89.60 ± 110.90 |

Ambulatory visits data come from City Clinic Sofia and Pulmed Hospital, Plovdiv

\( n \) number of patients.

\( \Delta \) Adis
screening for FH may allow for rapid and effective lipid management and for prevention of recurrent events, and thus may reduce the burden on the healthcare system. The recommendation in the hospital discharge document for implementation of cascade screening will help to identify close family members to ensure timely intervention and prevent cardiovascular events. Therefore, implementing an automated screening tool may be advantageous for physicians and so improve the identification of individuals with FH at the time of hospitalization.

ACKNOWLEDGEMENTS

The authors wish to thank the staff of the all participating hospitals and particularly to Dr. Dosev from City Clinic Achibadem Montana.

Funding. Amgen (Europe) GmbH designed the study in cooperation with the authors and provided financial support for the study, statistical analysis, including article processing charges and the open access fees.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work, and have given their approval for this version to be published.

Authorship Contributions. Ivo Petrov and Reneta Petkova contributed to conception and design of the study. Veselin Istatkov, Dimiter Mutafchiev and Boyang Zhao conducted the statistical analysis. All authors contributed to acquisition, analysis, and/or interpretation of data, critically revised the manuscript, gave final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy.

Disclosures. The authors disclose the following: Ivo Petrov has received research grants from Novartis, Amgen and Boerringer, consulting fees from Amgen, Actavis, Novartis, Medtronic, MSD, Boerringer and Pfizer and speaker honoraria from Amgen, Contego Medical and Medtronic. Arman Postadzhiyan discloses speaker honoraria from Amgen and Sanofi. Maria Tokmakova has received speaker honoraria from Bayer, Boerierger, Pfizer, Amgen, Astra Zeneca, Novo Nordisc, Berlin-Chemie and consulting fees from Bayer, Boerierger, Pfizer, Amgen, Astra Zeneca, Novo Nordisc, Berlin-Chemie. Ruslan Kasabov, Dobrin Vassilev and Fedya Nikolov have nothing to declare. Veselin Istatkov and Dimiter Mutafchiev are Sqilline employee. Boyang Zhao has received consulting fees from Sqilline and Quantality Research Group LLC, discloses partnership with Sqilline and Quantality Research Group LLC and is stockholder in Sqilline Health, Inc. Reneta Petkova is Amgen employee and Amgen stockholder.

Compliance with Ethics Guidelines. There was no patient involvement in this research study. The study was conducted in accordance with the Helsinki Declaration of 1964, as revised in 2013, and with country specific legal and regulatory requirements. It was approved by ethics committees and for registration or classification by regulatory bodies, as applicable in each hospital. In agreement with national law, the study protocol was approved by all five Ethics Commissions of the participating hospitals. The contract with the hospitals were signed as follows: UMBAL Alexandrovska—11.12.2019, City Clinic Achibadem Sofia—10.12.2019, UMBAL Pulmed Plovdiv—19.02.2020, UMBAL St Anna Sofia—17.03.2020, City Clinic Achibadem Montana—10.12.2019.
**Data Availability.** Qualified researchers may request data from Amgen clinical studies. Complete details are available at the following: http://www.amgen.com/datasharing.

**Open Access.** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

**REFERENCES**

1. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raaal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Boren J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J. 2013;34:3478–3490.

2. de Ferranti SD, Rodday AM, Mendelson MM, Wong JB, Leslie JK, Sheldrick RC. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States national health and nutrition examination surveys (NHANES). Circulation. 2016;133:1067–72.

3. Bucholz EM, Rodday AM, Kolor K, Khoury MJ, de Ferranti SD. Prevalence and predictors of cholesterol screening, awareness, and statin treatment among US adults with familial hypercholesterolemia or other forms of severe dyslipidemia (1999–2014). Circulation. 2018;137:2218–30.

4. De Backer G, Besseling J, Chapman J, et al; EURO-ASPIRE Investigators. Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology. Atherosclerosis. 2015; 241:169–175.

5. Nanchen D, Gencer B, Auer R, et al. Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. Eur Heart J. 2015;36:2438–45.

6. Nanchen D, Gencer B, Muller O, et al. Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes. Circulation. 2016;134:698–709.

7. Yudi M, Omera L, McCubbery N, Dick S, Jayasinghe R, Hamilton-Craig I. Suboptimal consideration and management of potential familial hypercholesterolaemia in patients with suspected premature coronary artery disease. Singapore Med J. 2012;53:174–8.

8. Pang J, Poulter EB, Bell DA, et al. Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit. J Clin Lipidol. 2015;9:703–8.

9. Danny Platform https://danny.sqilline.com/

10. Reiner Z, Catapano AL, De Backer G, et al. European association for cardiovascular prevention & rehabilitation, ESC/EAS guidelines for the management of dyslipidaemias: the task Force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS). Eur Heart J. 2011;32:1769–818.

11. Petrov I, Postadzhiyan A, Tokmakova M, Kitova L, Tsoniev S, Addison J, Petkova R, Lachev V (2018) Management of high and very high-risk subjects with familial hypercholesterolemia: results from an observational study in Bulgaria. Folia Medica 60(3): doi: https://doi.org/10.2478/folmed-2018-0020

12. Akioyamen LE, Genest J, Shan S.D, Reel RL, Albaum JM et al (2017) Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis, Br Med J Open 7:e016461.

13. Singh A, Gupta A, Collins BL, et al. Familial hypercholesterolemia among young adults with myocardial infarction. JACC. 2019;73(19):2439–50.

14. Al-Rasadi K, Al-Zakwani I, Alawi A, et al. Prevalence, management, and outcomes of familial
hypercholesterolemia in patients with acute coronary syndromes in the Arabian Gulf. J Clin Lipidol. 2018;12:685–92.

15. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol. 2004;160:407–20.

16. Watts GF, Pang J, Santos RD. Europe aspires to set the record straight on familial hypercholesterolaemia. Atherosclerosis. 2015;241:769–71.

17. Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014; 311(18):1870–82. 24825642. https://doi.org/10.1001/jama.2014.4030.

18. Wilson PWF, Polonsky TS, Miedema MD, Khera A, Kosinski AS, Kuvin JT; AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American college of cardiology American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2018. https://doi.org/10.1016/j.jacc.2018.11.004. [Epub ahead of print].

19. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, Heeringa J, Wittman JC, Lansberg PJ, Kastelein JJ, Sijbrands EJ. Efficacy of statins in familial hypercholesterolaemia: a long-term cohort study. BMJ. 2008;337:a2423;19001495.

20. Petrov I, Dumitrescu A, Snejdrlova M, Zafrir B, Wozakowska-Kaplon B, Abryva L, Pintaric` H, Bridges B, Petkova R. Clinical Management of High and Very High Risk Patients with Hyperlipidaemia in Central and Eastern Europe: An Observational Study. Adv Ther https://doi.org/10.1007/s12325-019-0879-1

21. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90.

22. Supplement A: correction factors lipid lowering drugs—http://www.daninag.com/documents/04-Prilojenie-2006-23-01-2006.pdf.

23. Garg S, et al. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial. JACC Cardiovasc Interv. 2011;4:432–41.

24. Zhao, et al. Role of euro SCORE II in predicting long-term outcome after percutaneous catheter intervention for coronary triple vessel disease or left main stenosis. Int J Cardiol. 2013;168:3273–9.

25. Farooq V, et al. Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation. 2013;128:141–51.

26. Collins R, et al. Interpretation of the evidence for efficacy and safety of statin therapy. Lancet. 2016;388:2532–61.